Latest News on PBH

Financial News Based On Company


Advertisement
Advertisement

A manager reports a passive stake above 5% in Prestige Consumer Healthcare (PBH).

https://www.stocktitan.net/sec-filings/PBH/schedule-13g-prestige-consumer-healthcare-inc-passive-investment-disc-63a9f61e5f8c.html
Fuller & Thaler Asset Management, Inc. has reported a passive stake of 5.33% in Prestige Consumer Healthcare Inc. (PBH), owning 2,527,139.37 common shares as of September 30, 2026. The investment manager holds sole voting power over 2,522,247.37 shares and sole dispositive power over all 2,527,139.37 shares, indicating a significant but non-controlling interest in the company. This disclosure was made via a Schedule 13G SEC filing.

how InvestingPro spotted Prestige Healthcare’s 46% decline By Investing.com

https://www.investing.com/news/investment-ideas/how-investingpro-spotted-prestige-healthcares-46-decline-93CH-5027824
InvestingPro's Fair Value analysis accurately predicted a 46% decline in Prestige Consumer Healthcare Inc. (NYSE:PBH) stock. In February 2025, the platform flagged PBH as significantly overvalued at $86.12, estimating its intrinsic worth at $50.69. By November 2026, the stock had fallen to $45.64, validating InvestingPro's initial assessment.

(PBH) Risk Channels and Responsive Allocation

https://news.stocktradersdaily.com/news_release/15/PBH_Risk_Channels_and_Responsive_Allocation_111226111202_1794543122.html
This article provides an in-depth analysis of Prestige Consumer Healthcare Inc. (NYSE: PBH), indicating a near-term neutral sentiment amidst mid and long-term weakness. It highlights an exceptional risk-reward setup, targeting a 14.1% gain versus 0.3% risk if support holds. The report details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop-loss levels.

Prestige Consumer Healthcare stock cuts fiscal 2027 outlook

https://www.ad-hoc-news.de/boerse/news/nebenwerte/prestige-consumer-healthcare-stock-cuts-fiscal-2027-outlook/70483451
Prestige Consumer Healthcare has lowered its fiscal 2027 outlook for revenue, adjusted earnings, and free cash flow due to supply problems with its Clear Eyes product, stemming from production variability at an acquired facility. Despite strong reported revenue growth driven by recent acquisitions, organic revenue declined, impacting the company's full-year guidance. The company's other portfolio items and acquisitions are still performing as expected.

Prestige Consumer Healthcare Inc. 2027 Q2 - Results - Earnings Call Presentation (NYSE:PBH) 2026-11-09

https://seekingalpha.com/article/4965360-prestige-consumer-healthcare-inc-2027-q2-results-earnings-call-presentation
Prestige Consumer Healthcare Inc. (NYSE:PBH) published its Q2 2027 earnings call presentation. The company reported EPS of $1.13, beating estimates by $0.06, and revenue of $336.31 million, a 22.69% year-over-year increase, beating estimates by $7.18 million. This presentation accompanies their earnings call for the quarter ending November 5, 2026.
Advertisement

Prestige Consumer Healthcare Q2 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:fc418bdbe094b:0-prestige-consumer-healthcare-q2-earnings-call-highlights/
Prestige Consumer Healthcare reported a 22.7% increase in fiscal second-quarter revenue, reaching $336.3 million, primarily due to recent acquisitions like Breathe Right and LaCorium. Despite this growth, the company lowered its full-year outlook for fiscal 2027, projecting revenue between $1.28 billion and $1.29 billion, as ongoing production disruptions affecting its Clear Eyes brand are expected to limit sales to less than $20 million. Management highlighted efforts to address these production issues and reiterated a focus on debt reduction, aiming for a year-end leverage ratio of approximately four times.

Jefferies lowers Prestige Brands stock price target to $51 on Clear Eyes uncertainty

https://in.investing.com/news/stock-market-news/jefferies-lowers-prestige-brands-stock-price-target-to-51-on-clear-eyes-uncertainty-93CH-5685046
Jefferies has reduced its price target for Prestige Brands Holdings Inc. (NYSE:PBH) to $51 from $55, maintaining a Hold rating due to ongoing uncertainty regarding the recovery of the Clear Eyes brand. Despite strong performance from the base business and recent acquisitions, the firm noted production issues at Clear Eyes and the associated costs and execution risks in the company's eye-drop manufacturing operations. This adjustment follows Prestige Consumer Healthcare Inc.'s recent downward revision of its full-year outlook, which overshadowed better-than-expected Q2 2026 earnings.

Prestige Consumer Healthcare (PBH) Stock Dropped, So What Is Driving Attention Now?

https://sg.finance.yahoo.com/news/prestige-consumer-healthcare-pbh-stock-151524866.html
Prestige Consumer Healthcare (PBH) saw its stock drop despite exceeding quarterly earnings and revenue expectations, primarily due to recent acquisitions. The stock is down significantly across various timeframes, indicating fading momentum. Analysts peg its fair value at $67.80, suggesting it is 35% undervalued, but potential risks like Clear Eyes supply issues and high net debt could impact this outlook.

Prestige Consumer Healthcare stock hits 52-week low at 42.5 USD

https://www.investing.com/news/company-news/prestige-consumer-healthcare-stock-hits-52week-low-at-425-usd-93CH-5008607
Prestige Consumer Healthcare Inc. (PBH) stock has fallen to a 52-week low of $42.50, representing a 26.07% decline over the past year. Despite this, InvestingPro analysis suggests the stock is undervalued, with a fair value approximately 25% above current levels. The company recently reported strong second-quarter earnings that surpassed analyst expectations but reduced its full-year outlook due to production issues with its Clear Eyes brand.

Prestige Consumer Healthcare stock hits 52-week low at 42.5 USD

https://ca.investing.com/news/stock-market-news/prestige-consumer-healthcare-stock-hits-52week-low-at-425-usd-93CH-4939636
Prestige Consumer Healthcare Inc. (PBH) stock has reached a 52-week low of $42.50, despite its recent Q2 earnings surpassing analyst expectations for profit and sales. InvestingPro analysis suggests the stock is undervalued, with a fair value approximately 25% above current levels. However, the company reduced its full-year outlook due to production challenges with its Clear Eyes brand, leading Jefferies to adjust its price target to $51 from $55 while maintaining a Hold rating.
Advertisement

Jefferies lowers Prestige Brands stock price target to $51 on Clear Eyes uncertainty

https://www.investing.com/news/analyst-ratings/jefferies-lowers-prestige-brands-stock-price-target-to-51-on-clear-eyes-uncertainty-93CH-5005855
Jefferies has reduced its price target for Prestige Brands Holdings Inc. (NYSE:PBH) to $51 from $55, maintaining a Hold rating due to ongoing uncertainty surrounding the recovery of its Clear Eyes brand. Despite strong performance in its base business and acquisitions, and potential long-term supply advantages from its eye-drop manufacturing, the firm cited costs, execution risks, and limited visibility into Clear Eyes' recovery timeline for the valuation reset. This adjustment comes even after Prestige Consumer Healthcare Inc. recently reported better-than-expected Q2 2026 results, but revised its full-year outlook downward due to Clear Eyes production issues.

Prestige Consumer Q2 2027 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62920730/prestige-consumer-q2-2027-earnings-call-transcript
Prestige Consumer Healthcare Inc. reported a 22.7% increase in Q2 revenue, driven by acquisitions of Breathe Right and Liquorium, though organic revenue slightly declined due to timing. The company updated its fiscal 2027 revenue outlook to $1,280 to $1,290 million and adjusted EPS to $4.48 to $4.55, primarily due to production issues with Clear Eyes. Management is focused on debt reduction and expects the acquisitions to contribute significantly to long-term growth in sleep and therapeutic skincare markets.

Prestige Consumer Healthcare earnings beat by $0.05, revenue topped estimates

https://uk.investing.com/news/earnings/prestige-consumer-healthcare-earnings-beat-by-005-revenue-topped-estimates-4961042
Prestige Consumer Healthcare (NYSE: PBH) reported strong second-quarter results, beating analyst estimates for both EPS and revenue. The company posted an EPS of $1.13 against an estimated $1.08, and revenue reached $336.3M, surpassing the $329.58M consensus. Despite this, the stock has seen declines over the past three and twelve months, and its financial health is rated as "great performance" by InvestingPro.

Prestige Consumer Healthcare: Fiscal Q2 Earnings Snapshot

https://sg.finance.yahoo.com/news/prestige-consumer-healthcare-fiscal-q2-111644405.html
Prestige Consumer Healthcare Inc. (PBH) reported strong fiscal second-quarter results, with profits of $25.3 million and adjusted earnings of $1.13 per share, surpassing Wall Street expectations. The medicine distributor also exceeded revenue forecasts, posting $336.3 million for the period. These results were generated by Automated Insights using data from Zacks Investment Research.

Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results

https://www.manilatimes.net/2026/11/05/tmt-newswire/globenewswire/prestige-consumer-healthcare-inc-reports-fiscal-2027-second-quarter-results/2462705
Prestige Consumer Healthcare Inc. announced its financial results for the second quarter and first half of fiscal 2027, ending September 30, 2026. The company reported a 22.7% increase in Q2 revenue to $336.3 million and an adjusted diluted EPS of $1.13, crediting strong brand performance and contributions from the Breathe Right® and LaCorium acquisitions. While overall guidance for fiscal 2027 revenue and adjusted diluted EPS was slightly lowered due to Clear Eyes® production variability, the outlook for the rest of the portfolio remains strong, with continued investment in growth and debt reduction.
Advertisement

Prestige Consumer Healthcare: Fiscal Q2 Earnings Snapshot

https://www.morning-times.com/ap/business/prestige-consumer-healthcare-fiscal-q2-earnings-snapshot/article_70fb7d11-cd5c-535d-a4c5-fda2947f27d9.html
Prestige Consumer Healthcare Inc. (PBH) reported a fiscal second-quarter profit of $25.3 million, or 53 cents per share. Adjusted for non-recurring costs, earnings were $1.13 per share, surpassing Wall Street expectations. The medicine distributor also exceeded revenue forecasts, posting $333.3 million for the period.

Prestige Consumer Healthcare (PBH) Beats Q2 Earnings and Revenue Estimates

https://finance.yahoo.com/healthcare/articles/prestige-consumer-healthcare-pbh-beats-113504164.html
Prestige Consumer Healthcare (PBH) reported Q2 earnings of $1.13 per share, exceeding the Zacks Consensus Estimate of $1.06, and revenues of $336.31 million, surpassing estimates by 2.31%. Despite these positive results, the company's shares have lost about 13.6% year-to-date, contrasting with the S&P 500's gain of 12.3%. The stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.

Prestige Consumer Healthcare Beats On Acquisitions, But A Clear Eyes Relapse Forces Another Guidance Cut

https://finviz.com/news/417289/prestige-consumer-healthcare-beats-on-acquisitions-but-a-clear-eyes-relapse-forces-another-guidance-cut
Prestige Consumer Healthcare reported a headline beat for its fiscal second quarter, largely driven by acquisitions like Breathe Right and LaCorium. However, the company cut its full-year guidance for revenue, EPS, and free cash flow due to persistent production issues with its Clear Eyes product at the recently acquired Pillar5 facility. The organic business, excluding acquisitions and Clear Eyes, showed modest growth, but the ongoing struggles with Clear Eyes continue to overshadow positive performance in other brands and acquisition benefits.

Prestige Consumer Healthcare Inc. (PBH) Seasonal returns chart

https://au.finance.yahoo.com/quote/PBH/seasonality/
This article from Yahoo Finance provides a seasonal returns chart for Prestige Consumer Healthcare Inc. (PBH), showing average monthly price returns from 2016 to 2026. It also includes current stock performance and details about an upcoming Q2 2027 earnings call.

Prestige Consumer Healthcare Inc. Estimates – NYSE:PBH

https://www.tradingview.com/symbols/NYSE-PBH/financials-estimates/
This article provides an overview of Prestige Consumer Healthcare Inc. (NYSE: PBH) financial estimates available on TradingView. It highlights that users can explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows for comparison of actual results with average, high, and low estimates, and visualization of trends over time.
Advertisement

Prestige Consumer Healthcare sets November 5 results for Prestige Consumer Healthcare stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/prestige-consumer-healthcare-sets-november-5-results-for-prestige-consumer-healthcare-stock/70378452
Prestige Consumer Healthcare (PBH) will publish its fiscal 2027 second-quarter and first-half results on November 5, 2026, before the market opens, with a conference call scheduled for 8:30 a.m. ET. The company's fiscal 2027 first-quarter revenue increased by 6.50 percent year over year to USD 265.71 million, and management has raised full-year revenue guidance to USD 1.29 billion to USD 1.315 billion. The upcoming report will provide an update on integration efforts from recent acquisitions and the impact of retailer order timing on the quarter.

Prestige Consumer Healthcare In (PBH) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_3290_QuantitativeReport_1791936000000
Argus has raised its target price for Prestige Consumer Healthcare (PBH) to $46.00, identifying it as a leading pure-play over-the-counter healthcare provider. The company boasts a diverse portfolio of strong brands within niche consumer health categories. The current price of PBH stock is $49.46.

Analysts cite USD 67.67 target for Prestige Consumer Healthcare stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/analysts-cite-usd-67-67-target-for-prestige-consumer-healthcare-stock/70349527
Analysts are setting a consensus price target of USD 67.67 for Prestige Consumer Healthcare (PBH) stock, significantly higher than its recent trading price of USD 49.92. The company reported first-quarter fiscal 2027 revenue of USD 265.71 million and adjusted EPS of USD 0.98. Investors are awaiting the upcoming second-quarter results scheduled for November 5, 2026, which will provide further insight into the company's financial trajectory.

Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?

https://www.tradingview.com/news/zacks:8016d0cef094b:0-is-it-apt-to-retain-prestige-consumer-stock-in-your-portfolio-now/
Prestige Consumer Healthcare (PBH) is focused on brand-building, supported by acquisitions like Breathe Right and LaCorium, and experiencing strong e-commerce growth. However, the company faces significant challenges including intense competition, pricing pressure, and foreign exchange fluctuations. Despite these headwinds, analysts project an 18.9% revenue increase for fiscal 2027, driven by recent acquisitions.

Results are scheduled before the market opens Nov. 5. The call is set for 8:30 a.m. ET.

https://www.stocktitan.net/news/PBH/prestige-consumer-healthcare-to-release-fiscal-2027-second-quarter-fskoy7z01skt.html
Prestige Consumer Healthcare (NYSE: PBH) announced it will release its fiscal 2027 second-quarter and first-half earnings on November 5, 2026, before the market opens. The company will host a conference call at 8:30 a.m. ET on the same day to discuss the results, with a live webcast and replay available on its Investor Relations page. The news of this earnings release led to a slight dip in PBH's stock price on October 14th.
Advertisement

How (PBH) Movements Inform Risk Allocation Models

https://news.stocktradersdaily.com/news_release/132/How_PBH_Movements_Inform_Risk_Allocation_Models_101326021601_1791915361.html
This article analyzes Prestige Consumer Healthcare Inc. (NYSE: PBH) using AI models to provide trading strategies and risk allocation insights. It identifies a near-term positive sentiment with a potential shift, a 44.3:1 risk-reward setup targeting a 13.2% gain, and divergent sentiment across different time horizons. The report details specific position, momentum breakout, and risk hedging strategies for traders.

Prestige Consumer Healthcare acquires Breathe Right for $1.045bn

https://scanx.trade/stock-market-news/companies/prestige-consumer-healthcare-acquires-breathe-right-for-1-045bn/43081514
Prestige Consumer Healthcare Inc. has acquired the Breathe Right brand and other associated brands from Foundation Consumer Healthcare for $1.045 billion. This strategic acquisition, which includes $150 million in tax benefits, makes Breathe Right the largest brand in Prestige's portfolio and expands its presence in the nasal strip category. The deal was financed through available cash and a new Term Loan B.

DEAN INVESTMENT ASSOCIATES, LLC's Prestige Consumer Healthcare Inc(PBH) Holding History

https://www.gurufocus.com/guru-portfolio/DEAN%20INVESTMENT%20ASSOCIATES,%20LLC/PBH
This article details DEAN INVESTMENT ASSOCIATES, LLC's historical holdings in Prestige Consumer Healthcare Inc (PBH). As of June 30, 2026, the firm holds 0 shares of PBH, resulting in 0% of its portfolio. Over time, DEAN INVESTMENT ASSOCIATES, LLC has made 11 purchases and 9 sales of PBH, with an estimated gain of $1.20 million, reflecting a 10.03% gain.

Prestige prices $400 million 6.25% notes due 2034

https://scanx.trade/stock-market-news/companies/prestige-consumer-healthcare-to-offer-400m-senior-notes-due-2034/44371374
Prestige Consumer Healthcare Inc. has priced a private offering of $400 million in 6.25% senior notes due 2034, issued by its subsidiary Prestige Brands, Inc. The proceeds, combined with cash on hand, will be used to redeem the company's outstanding $400 million 5.125% Senior Notes due January 2028 and cover related expenses. The sale is expected to close around July 15, 2026.

Prestige Consumer Healthcare stock falls 11% on Q4 revenue decline

https://scanx.trade/stock-market-news/companies/prestige-consumer-healthcare-stock-falls-11-on-q4-revenue-decline/43791805
Prestige Consumer Healthcare Inc. experienced an 11% stock decline after announcing disappointing Q4 2026 results, including a 5% year-over-year revenue drop and significant declines in its North America OTC Eye & Ear Care and International OTC segments. The decline was primarily attributed to supply chain constraints affecting its Clear Eyes® brand due to issues at the recently acquired Pillar5 facility. Consequently, Hagens Berman has launched an investigation into whether the company adequately disclosed these supply chain problems, potentially violating federal securities laws.
Advertisement

Transcript: Prestige Consumer Q1 2027 Earnings Conference Call

https://www.benzinga.com/news/26/10/62209659/transcript-prestige-consumer-q1-2027-earnings-conference-call
Prestige Consumer Healthcare Inc. (NYSE: PBH) reported a 6.5% sales increase to $266 million in Q1 2027, driven by strong performance in GI and skincare. The company completed strategic acquisitions of Breathe Right and Locorium Health, which are expected to significantly contribute to revenue and diversify its portfolio. Prestige raised its full-year revenue guidance to $1.29-$1.315 billion, anticipating over 20% growth from acquisitions while maintaining 1-3% organic growth.

Understanding Momentum Shifts in (PBH)

https://news.stocktradersdaily.com/news_release/81/Understanding_Momentum_Shifts_in_PBH_100326080002_1791028802.html
This article analyzes Prestige Consumer Healthcare Inc. (NYSE: PBH), highlighting weak sentiment across all time horizons and an exceptional 45.8:1 risk-reward short setup. It details institutional trading strategies, including long, breakout, and risk-hedging options, along with multi-timeframe signal analysis. The report suggests a short bias with significant downside potential against minimal risk.

More Than Half of U.S. Women Have Avoided Talking About an Intimate Wellness Concern Because They Felt Embarrassed or Uncomfortable, New Summer's Eve® Survey Finds – Company Announcement - FT.com

https://markets.ft.com/data/announce/detail?dockey=600-202609300918PR_NEWS_USPRX____NY59643-1
A new survey by Summer's Eve reveals that while 63% of U.S. women believe discussions around intimate wellness are more comfortable now than five years ago, 52% have personally avoided such conversations due to embarrassment. The "Let's Talk About It" initiative aims to bridge this gap by using humor and straightforward language to encourage open dialogue. The research highlights that even Gen Z experiences discomfort, and humor, combined with shared experiences and expert information, can help make these important conversations easier.

Prestige Consumer Healthcare Eyes Clear Eyes Recovery, $270M+ Free Cash Flow

https://es.tradingview.com/news/marketbeat:b0412d2e8094b:0-prestige-consumer-healthcare-eyes-clear-eyes-recovery-270m-free-cash-flow/
Prestige Consumer Healthcare is focusing on investing in established over-the-counter brands, maintaining high margins, and using free cash flow for debt reduction and acquisitions. A key challenge has been supply constraints for its Clear Eyes brand, impacting fiscal 2026 revenue, but the company expects increased supply in the latter half of fiscal 2027. They are also seeing tailwinds in their GI brands due to GLP-1 drug side effects and are expanding through strategic acquisitions like Breathe Right and LaCorium Health, while prioritizing debt reduction.

Prestige Consumer Healthcare Eyes Clear Eyes Recovery, $270M+ Free Cash Flow

https://www.tradingview.com/news/marketbeat:b0412d2e8094b:0-prestige-consumer-healthcare-eyes-clear-eyes-recovery-270m-free-cash-flow/
Prestige Consumer Healthcare (PBH) is focusing on established OTC brands, a high-margin operating model, and using free cash flow for debt reduction and acquisitions. The company faces supply constraints for its Clear Eyes brand, which impacted fiscal 2026 revenue, but expects recovery and organic growth in fiscal 2027. Prestige also discussed growth in its GI portfolio, recent acquisitions like Breathe Right and LaCorium Health, and its strategy for managing e-commerce and channel shifts.
Advertisement

Prestige Consumer Healthcare stock gains ahead of Sidoti event

https://www.ad-hoc-news.de/boerse/news/nebenwerte/prestige-consumer-healthcare-stock-gains-ahead-of-sidoti-event/70160612
Prestige Consumer Healthcare stock is seeing gains ahead of its scheduled presentation at the Sidoti Small-Cap Virtual Conference on September 24, 2026. The company, which sells consumer health products under established brands, will present from 10:00 to 10:30 a.m. Eastern Time. Investors are looking for quantified information on sales trends, profitability, or the outlook during this event to compare with its latest reported period.

How InvestingPro Fair Value spotted Prestige Healthcare’s 43% drop By Investing.com

https://m.investing.com/news/investment-ideas/how-investingpro-fair-value-spotted-prestige-healthcares-43-drop-93CH-4895518?ampMode=1
InvestingPro's Fair Value analysis accurately predicted a 43% drop in Prestige Consumer Healthcare Inc. (NYSE:PBH) stock by flagging it as significantly overvalued in February 2025. The stock's price subsequently declined from $86.12 to $48.70, validating the initial warning. This case study highlights the importance of intrinsic valuation in identifying overpriced stocks and avoiding potential losses.

Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference

https://www.moomoo.com/news/post/75968811/prestige-consumer-healthcare-inc-to-participate-in-barclays-global-consumer
Prestige Consumer Healthcare Inc. (NYSE: PBH) announced it will participate in the Barclays Global Consumer Conference. The company's President and CEO, Rajeev Lawrence, and CFO, Ron Chase, are scheduled to present on September 10, 2026, at 2:55 PM ET. A live webcast of the presentation will be available on the company's website.

Prestige Consumer Healthcare to host fireside chat at Barclays Global Consumer Conference

https://scanx.trade/stock-market-news/companies/prestige-consumer-healthcare-host-fireside-chat-barclays-global/50447753
Prestige Consumer Healthcare Inc. (NYSE: PBH) announced that its Chairman, President, and CEO Ron Lombardi, along with CFO and COO Christine Sacco, will lead a fireside chat at the Barclays Global Consumer Conference on September 10, 2026, at 12:45 pm ET. The session will be live-streamed on the company's investor relations website, with a replay available afterward. This event offers investors a direct opportunity to engage with management on the company's strategic direction and operational performance.

Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference

https://www.manilatimes.net/2026/09/09/tmt-newswire/globenewswire/prestige-consumer-healthcare-inc-to-participate-in-barclays-global-consumer-conference/2421075
Prestige Consumer Healthcare Inc. announced that its Chairman, President, & CEO Ron Lombardi and CFO and COO Christine Sacco will participate in a fireside chat at the Barclays Global Consumer Conference on September 10, 2026, at 12:45 p.m. ET. A live webcast and replay of the event will be available on the company's investor relations website. Prestige Consumer Healthcare is a leading consumer healthcare company with a diverse portfolio of trusted brands across multiple markets.
Advertisement

Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference

https://finance.yahoo.com/healthcare/articles/prestige-consumer-healthcare-inc-participate-210000701.html
Prestige Consumer Healthcare Inc. announced that Ron Lombardi, Chairman, President, & CEO, and Christine Sacco, CFO and COO, will participate in a fireside chat at the Barclays Global Consumer Conference on September 10, 2026, at 12:45 p.m. ET. A live webcast and replay of the event will be available on the company's investor relations website. The company is a leading consumer healthcare company with a diverse portfolio of trusted brands.

Check your homes: Recall covers 40,000 bottles of eye drops sold at Walmart, Target, Kroger

https://www.cleveland.com/news/2026/08/check-your-homes-recall-covers-40000-bottles-of-eye-drops-sold-at-walmart-target-kroger.html
Nearly 40,000 bottles of Clear Eyes Maximum Itchy Eye Relief eye drops have been recalled due to potential contamination and "lack of assurance sterility." The Class II recall, initiated by Prestige Brand Holdings, affects lot 2552A of 15ml bottles with an expiration date of September 30, 2027. These eye drops were distributed nationwide at major retailers including Walmart, Kroger, and Target, and consumers are advised to stop using them and return them for a refund.

40,000 bottles of eye drops across the US recalled over issues with sterility of product

https://www.theguardian.com/us-news/2026/aug/22/eyedrop-recall-clear-eyes
Nearly 40,000 bottles of Clear Eyes Maximum Itchy Eye Relief eye drops have been voluntarily recalled across the US by Prestige Brand Holdings due to concerns about a "lack of assurance of sterility." The FDA classified this as a Class II recall, indicating a moderate risk of temporary or medically reversible adverse health consequences. Consumers are advised to stop using the recalled product, which covers specific lot codes and expiration dates, and return them for a refund.

Nearly 40,000 eye drops recalled nationwide over possible contamination

https://www.foxbusiness.com/lifestyle/nearly-40000-eye-drops-recalled-nationwide-over-possible-contamination.amp
Prestige Brand Holdings is voluntarily recalling nearly 40,000 bottles of its Clear Eyes Maximum Itchy Eye Relief eye drops across the nation. The recall is due to a "lack of assurance of sterility" and is classified as a Class II recall by the FDA, indicating that use of the product may cause temporary or medically reversible adverse health consequences. The affected bottles have lot code 2552A and an expiration date of September 30, 2027.

Great Lakes Advisors LLC Takes $2.98 Million Position in Prestige Consumer Healthcare Inc. $PBH

https://www.marketbeat.com/instant-alerts/filing-great-lakes-advisors-llc-takes-298-million-position-in-prestige-consumer-healthcare-inc-pbh-2026-08-21/
Great Lakes Advisors LLC has acquired a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH), purchasing 63,058 shares valued at approximately $2.98 million, representing a 0.13% stake in the company. Institutional investors collectively own 99.95% of PBH. Prestige Consumer Healthcare exceeded quarterly expectations with $0.98 adjusted EPS and $265.71 million in revenue, though analyst ratings are mixed, with an average "Hold" rating and a price target of $70.75.
Advertisement

Clear Eyes eye drops recalled over sterility concerns

https://qz.com/clear-eyes-eye-drops-recall-prestige-consumer-healthcare-082026
Prestige Consumer Healthcare's Medtech Products Inc. is voluntarily recalling nearly 40,000 bottles of Clear Eyes Maximum Itchy Eye Relief eye drops due to sterility concerns, although no active contamination has been identified. The FDA classified this as a Class II recall, meaning serious health consequences are unlikely. Consumers are advised to stop using the product and may seek refunds from retailers.

Is Prestige Consumer Healthcare’s (PBH) Upgraded 2027 Outlook and Halted Buybacks Reframing Its Growth Story?

https://www.webull.com/news/15431111978427392
Prestige Consumer Healthcare Inc. (PBH) recently upgraded its fiscal 2027 outlook, projecting revenue of US$1.29 billion to US$1.32 billion and GAAP diluted EPS of US$4.18 to US$4.28, driven by new acquisitions. Despite this positive guidance and a planned operational transition, the company has halted share buybacks and still faces risks related to eye care supply reliability and integration complexity. Analysts are cautious, with some predicting lower revenue and earnings, highlighting the ongoing challenges that could impact the realization of the upgraded outlook.

Is Prestige Consumer Healthcare’s (PBH) Upgraded 2027 Outlook and Halted Buybacks Reframing Its Growth Story?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pbh/prestige-consumer-healthcare/news/is-prestige-consumer-healthcares-pbh-upgraded-2027-outlook-a/amp
Prestige Consumer Healthcare (PBH) has raised its fiscal 2027 outlook, projecting revenues of US$1.29-US$1.32 billion and GAAP diluted EPS of US$4.18-US$4.28, driven by new acquisitions. This updated guidance, alongside a halt in buybacks and an upcoming SVP of Operations retirement, aims to reframe the company's growth narrative, emphasizing the impact of recent acquisitions and supply chain investments despite underlying risks. The article also highlights a fair value estimate of $66.80 for PBH, suggesting a 32% upside.

Rice Hall James & Associates LLC Acquires Shares of 689,692 Prestige Consumer Healthcare Inc. $PBH

https://www.marketbeat.com/instant-alerts/filing-rice-hall-james-associates-llc-acquires-shares-of-689692-prestige-consumer-healthcare-inc-pbh-2026-08-18/
Rice Hall James & Associates LLC has acquired 689,692 shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) worth approximately $32.6 million, making it one of their largest holdings with a 1.46% stake. Institutional ownership of PBH remains high at 99.95%, with several other investment firms also increasing their positions. Despite exceeding quarterly earnings and revenue expectations, PBH shares traded down 2.8%, and analysts currently maintain a "Hold" rating with an average price target of $70.75.

Prestige Consumer Healthcare Announces Operations Leadership Transition

https://www.theglobeandmail.com/investing/markets/stocks/PBH/pressreleases/3871805/prestige-consumer-healthcare-announces-operations-leadership-transition/
Prestige Consumer Healthcare (PBH) announced that Senior Vice President of Operations, Jeffrey Zerillo, will retire on August 14, 2026, marking a leadership transition. Analysts have issued a Buy rating with a $72.00 price target for PBH, while TipRanks' AI Analyst, Spark, rates it as Outperform due to strong financial performance and a supportive earnings outlook. The company specializes in over-the-counter health and wellness products in North America.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement